Published in Clin Exp Immunol on February 25, 2008
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab (2010) 2.99
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med (2012) 2.05
The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs (2010) 1.86
Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. Mol Genet Metab (2012) 1.79
Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol (2008) 1.50
Pompe disease gene therapy. Hum Mol Genet (2011) 1.39
Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci U S A (2014) 1.10
The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PLoS One (2012) 1.04
CRIM-Negative Pompe Disease Patients with Satisfactory Clinical Outcomes on Enzyme Replacement Therapy. JIMD Rep (2012) 0.99
Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders. Nanomedicine (2011) 0.97
Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I. Mol Genet Metab (2012) 0.92
Immune response hinders therapy for lysosomal storage diseases. J Clin Invest (2008) 0.91
Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics. Expert Rev Clin Pharmacol (2013) 0.91
Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler's syndrome after pharmacological enzyme replacement therapy. Haematologica (2012) 0.88
Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease. Hum Vaccin Immunother (2012) 0.87
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles. Nat Nanotechnol (2016) 0.84
A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2-model applications. CPT Pharmacometrics Syst Pharmacol (2014) 0.81
Induction of immune tolerance to a therapeutic protein by intrathymic gene delivery. Mol Ther (2010) 0.81
Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease. Mol Genet Metab Rep (2014) 0.79
Immune Modulation Therapy in a CRIM-Positive and IgG Antibody-Positive Infant with Pompe Disease Treated with Alglucosidase Alfa: A Case Report. JIMD Rep (2011) 0.79
Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches. Cell Mol Immunol (2016) 0.77
Pompe's Disease in Childhood: A Metabolic Myopathy. Med J Armed Forces India (2011) 0.77
Administration of anti-CD3 antibodies modulates the immune response to an infusion of α-glucosidase in mice. Mol Ther (2012) 0.76
Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study. Wien Klin Wochenschr (2013) 0.76
The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders. J Inherit Metab Dis (2016) 0.75
Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe Disease. J Pharm Sci (2016) 0.75
A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease. Mol Genet Metab Rep (2017) 0.75
Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature (1991) 6.30
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67
Imaging the single cell dynamics of CD4+ T cell activation by dendritic cells in lymph nodes. J Exp Med (2004) 5.08
Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science (1989) 4.70
Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med (2001) 3.60
Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) (2005) 3.42
Mycophenolate mofetil and its mechanisms of action. Immunopharmacology (2000) 3.41
CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest (2003) 2.97
The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol (1996) 2.77
Toward a better understanding of methotrexate. Arthritis Rheum (2004) 2.69
The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest (1993) 2.66
The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol (1992) 2.53
Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem (1998) 2.24
Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction. Curr Pharm Biotechnol (2002) 1.81
Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest (1998) 1.79
Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation (1997) 1.52
Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood (1999) 1.34
Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics (2004) 1.31
Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I. Proc Natl Acad Sci U S A (2004) 1.30
The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum (1989) 1.28
Human immune response to recombinant human proteins. J Pharm Sci (2001) 1.23
Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med (1985) 1.23
Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) (2003) 1.20
Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med (2003) 1.20
Regulation of B-cell commitment to plasma cells or to memory B cells. Semin Immunol (1997) 1.14
Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet (2003) 1.13
An hour after immunization peritoneal B-1 cells are activated to migrate to lymphoid organs where within 1 day they produce IgM antibodies that initiate elicitation of contact sensitivity. J Immunol (2005) 1.07
The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine. Arthritis Rheum (1990) 1.06
Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease. Clin Exp Immunol (2004) 0.99
Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice. Clin Exp Immunol (1999) 0.92
Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis. Rheumatol Int (2003) 0.88
Effect of low dose methotrexate on neutrophil chemotaxis induced by leukotriene B4 and complement C5a. J Rheumatol (1987) 0.87
Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia. Blood (1991) 0.85
Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. Med Pediatr Oncol (1995) 0.85
Activation-dependent lymphocyte apoptosis induced by methotrexate. Transplant Proc (1998) 0.85
Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis. Rheumatology (Oxford) (2000) 0.85
Suppression of B cell function by methotrexate and trimetrexate. Evidence for inhibition of purine biosynthesis as a major mechanism of action. J Immunol (1988) 0.82
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell (1991) 17.00
Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell (1991) 12.27
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet (2007) 6.29
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem (1992) 3.48
Evidence-based recommendations for the role of exercise in the management of osteoarthritis of the hip or knee--the MOVE consensus. Rheumatology (Oxford) (2004) 3.38
Decreased expression of myotonin-protein kinase messenger RNA and protein in adult form of myotonic dystrophy. Science (1993) 2.75
The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry (1991) 2.49
Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. IARC Monogr Eval Carcinog Risk Chem Hum Suppl (1980) 1.99
Termination of DNA synthesis by novel 3'-modified-deoxyribonucleoside 5'-triphosphates. Nucleic Acids Res (1994) 1.95
Major antigenic proteins of the agent of human granulocytic ehrlichiosis are encoded by members of a multigene family. Infect Immun (1998) 1.72
Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol (1997) 1.72
Exercise induced critical ischaemia of the upper limb secondary to a cervical rib. Br J Sports Med (2003) 1.72
Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). Br J Haematol (1991) 1.70
Gender differences in symptom presentation associated with coronary heart disease. Am J Cardiol (1999) 1.69
Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia. Arch Dis Child (1987) 1.68
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood (2001) 1.67
Nominal group technique: a process for identifying diabetes self-care issues among patients and caregivers. Diabetes Educ (2000) 1.65
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia (2003) 1.64
Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord (2004) 1.64
Therapeutic interventions for Burkitt's lymphoma in children. Cochrane Database Syst Rev (2006) 1.61
AphidBase: a centralized bioinformatic resource for annotation of the pea aphid genome. Insect Mol Biol (2010) 1.57
32P-incorporation PCR for the detection of rearrangements at the TCR-gamma locus. Diagn Mol Pathol (1996) 1.52
Molecular cloning and sequencing of three granulocytic Ehrlichia genes encoding high-molecular-weight immunoreactive proteins. Infect Immun (1998) 1.50
Three cases of triploidy in man. Cytogenetics (1967) 1.48
A treatment for carpal tunnel syndrome: results of follow-up study. J Manipulative Physiol Ther (1994) 1.43
Antidepressant use over time in a rural older adult population: the MoVIES Project. J Am Geriatr Soc (1997) 1.42
Clinical examination of varicose veins--a validation study. Ann R Coll Surg Engl (2000) 1.42
Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia (2009) 1.40
Fine structure of the human FMR1 gene. Hum Mol Genet (1993) 1.30
Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia (2003) 1.28
The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study. Br J Haematol (2000) 1.28
Completeness of case ascertainment and survival time error in English cancer registries: impact on 1-year survival estimates. Br J Cancer (2011) 1.24
Long survival in childhood lymphoblastic leukaemia. Br J Cancer (1987) 1.23
Neurotoxicity in lymphoblastic leukaemia: comparison of oral and intramuscular methotrexate and two doses of radiation. Arch Dis Child (1990) 1.22
Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J (2014) 1.22
Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia (2004) 1.21
Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol (1989) 1.20
Essential characteristics of self-determined behavior of individuals with mental retardation. Am J Ment Retard (1996) 1.18
Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts. Br J Cancer (1994) 1.15
Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia (2003) 1.15
Control of Drosophila perineurial glial growth by interacting neurotransmitter-mediated signaling pathways. Proc Natl Acad Sci U S A (2001) 1.09
Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol (2001) 1.08
Credit where credit is due. The Haneke-Marini suture: not a "new" technique. Dermatol Surg (1995) 1.07
CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol (2003) 1.06
Haplotype analysis of SNAP-25 suggests a role in the aetiology of ADHD. Mol Psychiatry (2004) 1.05
MRC UKALL X. The UK protocol for childhood ALL: 1985-1990. The Medical Research Council Working Party on Childhood Leukaemia. Leukemia (1992) 1.01
Serotonergic system and attention deficit hyperactivity disorder (ADHD): a potential susceptibility locus at the 5-HT(1B) receptor gene in 273 nuclear families from a multi-centre sample. Mol Psychiatry (2002) 1.00
Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease. Clin Exp Immunol (2004) 0.99
Symptom predictors of acute coronary syndromes in younger and older patients. Nurs Res (2001) 0.98
Recognition of medically unexplained symptoms--do doctors agree? J Psychosom Res (1999) 0.98
Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia. Br J Haematol (1998) 0.97
Sex steroids, meibomian gland dysfunction and evaporative dry eye in Sjögren's syndrome. Lupus (2002) 0.96
Management of nasal injuries: a postal questionnaire survey of UK ENT consultants. J Laryngol Otol (2002) 0.95
Psychological aspects of donor insemination: evaluation and follow-up of recipient couples. Fertil Steril (1992) 0.95
Association study of a dopamine transporter polymorphism and attention deficit hyperactivity disorder in UK and Turkish samples. Mol Psychiatry (2001) 0.94
Monosomy 20 as a pointer to dicentric (9;20) in acute lymphoblastic leukemia. Leukemia (2000) 0.93
A full-length cDNA resource for the pea aphid, Acyrthosiphon pisum. Insect Mol Biol (2010) 0.93
Analysis of a new class I gene mapping to the Hmt region of the mouse. Immunogenetics (1989) 0.93
Attention deficit hyperactivity disorder (ADHD) and the dopamine D4 receptor gene: evidence of association but no linkage in a UK sample. Mol Psychiatry (2001) 0.92
Acute myeloid leukaemia in childhood: the costs and benefits of intensive treatment. Br J Haematol (1991) 0.91
Comparison of the lymphocyte transformation test with the tuberculin test in rhesus monkeys and chimpanzees. Am J Vet Res (1970) 0.91
Familial acanthosis nigricans. A longitudinal study. J Reprod Med (1987) 0.91
Bone-marrow transplantation has a limited role in prolonging second marrow remission in childhood lymphoblastic leukaemia. Lancet (1986) 0.90
Molecular definition of a mitochondrially encoded mouse minor histocompatibility antigen. Cold Spring Harb Symp Quant Biol (1989) 0.90
Pharmacy services in family medicine residencies. Survey of clinics associated with Canadian residency programs. Can Fam Physician (1994) 0.90
The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br J Haematol (1999) 0.90
Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst Rev (2005) 0.90
High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J Clin Oncol (2000) 0.90
Late relapsing childhood lymphoblastic leukemia. Blood (1998) 0.89
Subcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravis. J Neuroimmunol (1999) 0.89
All our patients need to know about intensified diabetes management they learned in fourth grade. Diabetes Educ (2001) 0.89
Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial. Leukemia (2012) 0.88
The significance of random breath alcohol sampling in the accident and emergency department. Alcohol Alcohol (1987) 0.88
Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia. Med Pediatr Oncol (1990) 0.87
Opioid neurotoxicity: fentanyl-induced exacerbation of cerebral ischemia in rats. Brain Res (1999) 0.87
Detection and biochemical characteristics of the receptor for complexes of soluble CD14 and bacterial lipopolysaccharide. J Immunol (1997) 0.87
Diagnosis of Duchenne and Becker muscular dystrophies by polymerase chain reaction. A multicenter study. JAMA (1992) 0.87
IMPROVE: bridge over troubled waters. Jt Comm J Qual Improv (1998) 0.86
Is there a reservoir of sub-clinical lymphogranuloma venereum and non-LGV Chlamydia trachomatis infection in men who have sex with men? Int J STD AIDS (2008) 0.86
gamma-aminobutyric acid type B receptors are expressed and functional in mammalian cardiomyocytes. Proc Natl Acad Sci U S A (2000) 0.86
Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5,659 children. Br J Haematol (2010) 0.85
Stimulation of anti-influenza cytolytic T lymphocytes by a synthetic peptide of the influenza hemagglutinin can be modulated by at least three independent helper factors. J Immunol (1984) 0.85
Hyperprolactinaemia, amenorrhoea and galactorrhoea due to a pituitary thyrotroph adenoma. Clin Endocrinol (Oxf) (1985) 0.84
Treating fibromyalgia. Rheumatology (Oxford) (2000) 0.83
Urbanization, roads, and rural population change in the Ecuadorian Andes. Stud Comp Int Dev (1990) 0.83
Cutaneous lip tumours treated with Mohs micrographic surgery: clinical features and surgical outcome. Br J Dermatol (2005) 0.83
CD4 cell counts used as surrogate test for HIV infection. BMJ (1995) 0.83
Competing HMOs collaborate to improve preventive services. Jt Comm J Qual Improv (1995) 0.83
E. coli O157 phage type 21/28 outbreak in North Cumbria associated with pasteurized milk. Epidemiol Infect (2002) 0.83
Intrarater and interrater reliability of strength measurements of the biceps and deltoid using a hand held dynamometer. J Orthop Sports Phys Ther (1988) 0.82
Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database Syst Rev (2006) 0.82
Evolution in a spatially structured population subject to rare epidemics. Phys Rev E Stat Nonlin Soft Matter Phys (2001) 0.82
Opioid neurotoxicity: fentanyl dose-response effects in rats. Anesth Analg (1996) 0.82